Iwai Masaru, Horiuchi Masatsugu
Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa, Tohon, Ehime, Japan.
Hypertens Res. 2009 Jul;32(7):533-6. doi: 10.1038/hr.2009.74. Epub 2009 May 22.
Recent studies have established a new regulatory axis in the renin-angiotensin system (RAS). In this axis, angiotensin (Ang)-(1-7) is finally produced from Ang I or Ang II by the catalytic activity of angiotensin-converting enzyme 2 (ACE2). Ang-(1-7) shows actions different from those of AT(1) receptor stimulation, such as vasodilatation, natriuresis, anti-proliferation and an increase in the bradykinin-NO (nitric oxide) system. As the catalytic efficiency of ACE2 is approximately 400-fold higher with Ang II as a substrate than with Ang I, this axis is possibly acting as a counter-regulatory system against the ACE/Ang II/AT(1) receptor axis. The signaling pathway of the ACE2-Ang-(1-7) axis has not yet been totally and clearly understood. However, a recent report suggests that the Mas oncogene acts as a receptor for Ang-(1-7). Intracellular signaling through Mas is not clear yet. Several factors such as Akt phosphorylation, protein kinase C activation and mitogen-activated protein (MAP) kinase inhibition seem to be involved in this signaling pathway. Further investigations are needed to clarify the regulation and mechanism of action of ACE2 and Ang-(1-7). However, this second axis through ACE2 and Ang-(1-7) in RAS can be an important target for the therapy of cardiovascular and metabolic disorders.
最近的研究在肾素-血管紧张素系统(RAS)中确立了一条新的调节轴。在该轴中,血管紧张素(Ang)-(1-7)最终由血管紧张素转换酶2(ACE2)的催化活性从Ang I或Ang II产生。Ang-(1-7)表现出与AT(1)受体刺激不同的作用,如血管舒张、利钠、抗增殖以及缓激肽-一氧化氮(NO)系统的增强。由于ACE2以Ang II为底物时的催化效率比以Ang I为底物时高约400倍,该轴可能作为对抗ACE/Ang II/AT(1)受体轴的反调节系统。ACE2-Ang-(1-7)轴的信号通路尚未完全清楚地了解。然而,最近的一份报告表明,Mas癌基因作为Ang-(1-7)的受体。通过Mas的细胞内信号传导尚不清楚。诸如Akt磷酸化、蛋白激酶C激活和丝裂原活化蛋白(MAP)激酶抑制等几个因素似乎参与了该信号通路。需要进一步研究以阐明ACE2和Ang-(1-7)的调节和作用机制。然而,RAS中通过ACE2和Ang-(1-7)的这第二条轴可能成为心血管和代谢紊乱治疗的重要靶点。